The Medical Briefing  Nephrology

Tonsillectomy in IgA nephropathy, OPTI-MRC, dapagliflozin in dialysis, kidney biopsy on antiplatelet therapy

Retrospective no. 2/12

The essentials in four articles

■ Glomerular disease
Non-randomized prospective study of 221 Caucasian patients: long-term remission 90.4% vs 50.0% and kidney progression 3.5% vs 28.9% when tonsillectomy is added to immunosuppression. Single-center study, to be confirmed by randomized trials.

■ CKD and dialysis
Multiprofessional proposals for the CKD pathway: laboratory screening (creatinine, GFR, albuminuria), earlier nephrology review from stage 2, shared follow-up between GP, nephrologist and pharmacist, therapeutic education and quality indicators.

■ CKD and dialysis
80 patients on hemodialysis or peritoneal dialysis for 24 weeks: no significant fall in NT-proBNP (p = 0.065), and no effect on quality of life, walk test, echocardiography or troponin. Well tolerated; the benefits of SGLT2 inhibitors may require residual kidney function.

■ Clinical nephrology
1,103 consecutive biopsies (26% grafts), 143 on continued antiplatelet therapy: serious complications 6.3% vs 4.0% (not significant), but more transfusions (4.2% vs 1.5%). Argues against systematic withdrawal when thrombotic risk or diagnostic urgency is high.